VivoSeq
Other

Desensitization

0

Pipeline Programs↗

4

Active Trials↗

2

Companies Involved↗

Desensitization is an early-stage landscape with 0 programs across 2 companies. The most active players are Aimmune Therapeutics, Inc., Hansa Biopharma AB.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

78/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Aimmune Therapeutics, Inc.

0 programs

PreclinicalH

Hansa Biopharma AB

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

28

clinical trials

Completed14 · 50%
Unknown status6 · 21%
Active, not recruiting3 · 11%
Terminated3 · 11%
Withdrawn1 · 4%
Enrolling by invitation1 · 4%

Clinical Trials

Trial Activity

28 trials

Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
Active, not recruiting·HHansa Biopharma AB·N/A·NCT05714514·64 enrolled
Daratumumab and Belatacept for Desensitization
Active, not recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT04827979·19 enrolled
Carfilzomib and Belatacept for Desensitization
Active, not recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT05017545·21 enrolled
Daratumumab in HLA Desensitization Prior to Transplantation
Enrolling by invitation·—·Phase 2·NCT05300451·10 enrolled
The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.
Completed·JJapan Blood Products Organization·Phase 2/3·NCT02032095·17 enrolled
Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx
Completed·HHansa Biopharma AB·Phase 3·NCT04935177·64 enrolled
Cough Desensitization Therapy: Pilot 2
Completed·UUniversity of Montana·Phase 1·NCT05226299·22 enrolled
Investigating the Effect of Pulsatile Administration of Oxytocin on the Desensitization of Human Myometrium In-vitro
Completed·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·N/A·NCT02338089·18 enrolled
Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT
Completed·AAimmune Therapeutics, Inc.·Phase 2·NCT01987817·56 enrolled
Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization
Completed·—·Phase 4·NCT00555971·16 enrolled
Recovery of Oxytocin Responsiveness in Pregnant Human Myometrial Explants After Oxytocin-Induced Desensitization
Completed·SSamuel Lunenfeld Research Institute, Mount Sinai Hospital·N/A·NCT02051231·22 enrolled
Peanut Oral Immunotherapy Study of Early Intervention for Desensitization
Completed·AAimmune Therapeutics, Inc.·Phase 3·NCT03736447·146 enrolled
Mechanisms of Desensitization During Peanut Oral Immunotherapy
Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT01814241·20 enrolled
Ixazomib for Desensitization
Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT03213158·10 enrolled
Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study
Completed·AAimmune Therapeutics, Inc.·Phase 2·NCT02198664·47 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)